Protease, serine, 50 (PRSS50) Kits ELISA

Mouse (Murine) Protease, serine, 50 (PRSS50) interaction partners

1. TSP50 expression at embryonic day 6.5 (E6.5), day 8.5 (E8.5) and day 10.5 (E10.5) was increasingly enhanced, However, the expression of TSP50 decreased gradually in the development and differentiation of cardiac myocyte from E12.5 to postnatal (P0).

2. findings indicate that BORIS-induced expression of TSP50 is governed by accessibility and binding of BORIS to the promoter

3. TSP50 promotes cell proliferation, at least partially, through activation of the NF-kappaB signalling pathway.

4. results showed that downregulation of TSP50 expression in P19 embryonal carcinoma stem cells not only reduced cell proliferation, colony formation, and migration but also induced cell apoptosis

5. TSP50 may perform a critical biologic function in mammalian spermatogenesis. It may be a new type of threonine protease whose linear catalytic structure is similar to many serine proteases, except for a Thr-for-Ser residual catalytic site substitution.

6. These findings suggested that DNA methylation might regulate the TSP50 and mTSP50 gene expressions in different types of tissues and spermatic cells.

Human Protease, serine, 50 (PRSS50) interaction partners

1. TSP50 promotes the proliferation, migration and invasion of gastric cancer cells involving NF-kappaB dependent EMT activation. Targeting TSP50 may provide a novel therapeutic strategy for the management of gastric cancer

2. human epidermal growth factor receptor 2 (HER-2) levels, were correlated well with TSP50/p-Samd2/3 and TSP50/p27 expression status. Thus, our studies revealed a novel regulatory mechanism underlying TSP50-induced cell proliferation and provided a new favorable intervention target for the treatment of breast cancer

3. In patients with Colon cancer, the expression of TSP50 gene was associated with a poor prognosis.

4. TSP50 plays a significant role in NSCLC cell proliferation and may act as a novel oncogene in the development and progression of NSCLC.

5. Results suggest that 7P3A, which consists of 70 % 25-methoxyl-dammarane-3beta, 12beta, 20-triol and 30 % artemisinin, exhibits anti-cancer effects, in part, through downregulation of testes-specific protease 50 (TSP50) expression.

6. Results show that TSP50 is up-regulated in laryngocarcinoma tumour tissues and its down-regulation inhibits cell proliferation, reduces cell migration and induces cell apoptosis of laryngocarcinoma in NF-KB mediated pathway.

7. we found that some breast cancer diagnosis-associated features such as tumor size, tumor grade, estrogen receptors (ER) and progesterone receptors (PR) levels, were correlated well with TSP50/p65 and TSP50/MMP9 expression status

8. TSP50's threonine protease activity is crucial for its effects on tumor formation.

9. The mutations in the catalytic triad of TSP50 could significantly depressed TSP50-mediated cell proliferation and tumor formation.

10. High TSP50 expression is associated with laryngocarcinoma.

11. the importance of threonine 310, the most critical protease catalytic site in TSP50, to TSP50-induced cell proliferation and tumor formation

12. TSP50 is a potential effective indicator of poor survival for colorectal carcinoma patients, especially for those with early-stage tumors.

13. Results strongly suggest that bFGF mediates TSP50 downregulation by ERK1/2 activation, leading to the phosphorylation of Sp1 in this process.

14. TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells.

15. TSP50 was largely downregulated in all testicular germ cell tumors. It may function in mammalian spermatogenesis. Its linear catalytic structure is similar to many serine proteases, except for a Thr-for-Ser residual catalytic site substitution.

16. Overexpression of Sp1 and C/EBPbeta transcriptional factors upregulated the activities of the TSP50 promoter.

17. These findings suggested that DNA methylation might regulate the TSP50 and mTSP50 gene expressions in different types of tissues and spermatic cells.